SCHEMBL16339809

SCHEMBL16339809

Cc1cc(C)n(C2CNC2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.39
HTR2A P28223 3/20 0.35
DRD2 P14416 1/20 0.35
HRH1 P35367 1/20 0.35
ALDH1A1 P00352 4/20 0.35
GAA P10253 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 2/20 0.34
GLA P06280 1/20 0.34
HTR2C P28335 2/20 0.34
HTR2B P41595 2/20 0.34
KCNH2 Q12809 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GLS O94925 1/20 0.33
TSHR P16473 1/20 0.33
LMNA P02545 2/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15942127 0.85 KDM5A (0.38) KDM5ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL30022464 0.83 F10 (0.42) KDM5ASMN1; SMN2HTR2A
SCHEMBL15935405 0.81 SMN1; SMN2 (0.41) KDM5ASMN1; SMN2HTR2ADRD2HRH1
SCHEMBL2852441 0.81 MEN1 (0.46) KDM5ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL23748795 0.78 KDM4E (0.46) KDM5ASMN1; SMN2DRD2ALDH1A1KDM4E
SCHEMBL31462462 0.76 ALDH1A1 (0.49) KDM5ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL3364096 0.76 ALDH1A1 (0.49) KDM5ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL28720539 0.74 SMN1; SMN2 (0.38) KDM5ASMN1; SMN2HTR2ADRD2HRH1
SCHEMBL15832226 0.73 SIGMAR1 (0.43) KDM5ASMN1; SMN2HTR2ADRD2HRH1
SCHEMBL13135665 0.73 ALOX15 (0.51) KDM5ASMN1; SMN2HTR2ADRD2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107660199-B Piperazine carbamates and methods of making and using the same H.隆德贝克有限公司 2021-11-23 CN disclosed
EP-3271352-B1 PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME H LUNDBECK AS (DK) 2021-05-12 EP disclosed
US-20190084981-A1 Bromodomain Inhibitors ABBVIE INC (US) 2019-03-21 US disclosed
US-10131657-B2 Bromodomain inhibitors ABBVIE INC. (US) 2018-11-20 US disclosed
US-9994537-B2 Piperazine carbamates and methods of making and using same ABIDE THERAPEUTICS, INC. (US) 2018-06-12 US disclosed
US-9957263-B2 Bromodomain inhibitors ABBVIE INC. (US) 2018-05-01 US disclosed
EP-3271352-A2 PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME Abide Therapeutics, Inc. (US) 2018-01-24 EP disclosed
US-20170334874-A1 PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2017-11-23 US disclosed
US-9771341-B2 Piperazine carbamates and methods of making and using same ABIDE THERAPEUTICS, INC. (US) 2017-09-26 US disclosed
WO-2016149401-A2 PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME ABIDE THERAPEUTICS, INC. (US) 2016-09-22 WO disclosed
US-20160272602-A1 PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2016-09-22 US disclosed
US-20160272630-A1 Bromodomain Inhibitors ABBVIE INC. (US) 2016-09-22 US disclosed
US-20160185769-A1 Bromodomain Inhibitors ABBVIE INC. (US) 2016-06-30 US disclosed
EP-3013827-A1 BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-05-04 EP disclosed
EP-3013828-A1 BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-05-04 EP disclosed
WO-2014206150-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-12-31 WO disclosed
WO-2014206345-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272602-A1 PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME ABHD6, RABL6, ABHD16A KDM5A 441/4885SMN1; SMN2 2229/4885HTR2A 2110/4885
US-20190084981-A1 Bromodomain Inhibitors BRD4, BRD1, BRD3 KDM5A 584/4885SMN1; SMN2 2361/4885HTR2A 2510/4885
US-10131657-B2 Bromodomain inhibitors BRD1, BRD4, BRD3 KDM5A 679/4885SMN1; SMN2 2287/4885HTR2A 2365/4885
US-20170334874-A1 PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME ABHD6, RABL6, ABHD16A KDM5A 441/4885SMN1; SMN2 2229/4885HTR2A 2110/4885
US-20160272630-A1 Bromodomain Inhibitors BRD4, BRDT, EP300 KDM5A 1759/4885SMN1; SMN2 2310/4885HTR2A 4121/4885
US-20160185769-A1 Bromodomain Inhibitors BRD1, BRD4, BRD3 KDM5A 679/4885SMN1; SMN2 2287/4885HTR2A 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.